
Aktis Oncology
Biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor investor | €0.0 | round |
investor investor investor investor investor investor investor | €0.0 | round | |
investor investor investor investor investor investor | €0.0 | round | |
investor | €0.0 | round | |
* | $175m | Series B | |
Total Funding | 000k |
Related Content
Aktis Oncology is a pioneering biotech company focused on developing novel radiotherapies for cancer patients with unmet medical needs. Operating in the oncology market, Aktis targets a broad set of commonly occurring cancers, aiming to revolutionize cancer treatment by putting solid tumors into remission. The company serves patients who have limited treatment options, providing them with innovative therapeutic solutions.
Aktis Oncology's business model revolves around the research, development, and commercialization of transformative cancer therapies. The company generates revenue through the development and licensing of its proprietary radiotherapy molecules, as well as potential partnerships with pharmaceutical companies. By focusing on groundbreaking science and clinical development, Aktis aims to bring new hope to cancer patients worldwide.
Keywords: radiotherapies, cancer treatment, solid tumors, oncology, biotech, unmet needs, innovative therapies, clinical development, proprietary molecules, partnerships.